Logo image of VRNA

VERONA PHARMA PLC - ADR (VRNA) Stock Fundamental Analysis

NASDAQ:VRNA - US9250501064 - ADR

106.31 USD
+0.07 (+0.07%)
Last: 9/5/2025, 8:00:02 PM
106.31 USD
0 (0%)
After Hours: 9/5/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, VRNA scores 3 out of 10 in our fundamental rating. VRNA was compared to 195 industry peers in the Pharmaceuticals industry. While VRNA seems to be doing ok healthwise, there are quite some concerns on its profitability. VRNA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VRNA has reported negative net income.
In the past year VRNA has reported a negative cash flow from operations.
VRNA had negative earnings in each of the past 5 years.
In the past 5 years VRNA always reported negative operating cash flow.
VRNA Yearly Net Income VS EBIT VS OCF VS FCFVRNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -31.17%, VRNA perfoms like the industry average, outperforming 50.26% of the companies in the same industry.
VRNA has a Return On Equity (-72.35%) which is in line with its industry peers.
Industry RankSector Rank
ROA -31.17%
ROE -72.35%
ROIC N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
VRNA Yearly ROA, ROE, ROICVRNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

Looking at the Gross Margin, with a value of 33.49%, VRNA is in line with its industry, outperforming 57.44% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for VRNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRNA Yearly Profit, Operating, Gross MarginsVRNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

VRNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VRNA has more shares outstanding
Compared to 5 years ago, VRNA has more shares outstanding
Compared to 1 year ago, VRNA has a worse debt to assets ratio.
VRNA Yearly Shares OutstandingVRNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
VRNA Yearly Total Debt VS Total AssetsVRNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

VRNA has an Altman-Z score of 17.25. This indicates that VRNA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of VRNA (17.25) is better than 92.31% of its industry peers.
VRNA has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
VRNA has a Debt to Equity ratio of 1.07. This is in the lower half of the industry: VRNA underperforms 73.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Altman-Z 17.25
ROIC/WACCN/A
WACC9.24%
VRNA Yearly LT Debt VS Equity VS FCFVRNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 8.86 indicates that VRNA has no problem at all paying its short term obligations.
The Current ratio of VRNA (8.86) is better than 79.49% of its industry peers.
VRNA has a Quick Ratio of 8.73. This indicates that VRNA is financially healthy and has no problem in meeting its short term obligations.
VRNA has a better Quick ratio (8.73) than 80.51% of its industry peers.
Industry RankSector Rank
Current Ratio 8.86
Quick Ratio 8.73
VRNA Yearly Current Assets VS Current LiabilitesVRNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.54% over the past year.
The Revenue has been growing slightly by 1.86% on average over the past years.
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

VRNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.72% yearly.
Based on estimates for the next years, VRNA will show a very strong growth in Revenue. The Revenue will grow by 123.42% on average per year.
EPS Next Y123.49%
EPS Next 2Y74.39%
EPS Next 3Y58.05%
EPS Next 5Y57.72%
Revenue Next Year994.08%
Revenue Next 2Y340.75%
Revenue Next 3Y203.91%
Revenue Next 5Y123.42%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRNA Yearly Revenue VS EstimatesVRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
VRNA Yearly EPS VS EstimatesVRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VRNA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 47.27, which means the current valuation is very expensive for VRNA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VRNA indicates a somewhat cheap valuation: VRNA is cheaper than 68.72% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.69. VRNA is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 47.27
VRNA Price Earnings VS Forward Price EarningsVRNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRNA Per share dataVRNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

VRNA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as VRNA's earnings are expected to grow with 58.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y74.39%
EPS Next 3Y58.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VRNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VERONA PHARMA PLC - ADR

NASDAQ:VRNA (9/5/2025, 8:00:02 PM)

After market: 106.31 0 (0%)

106.31

+0.07 (+0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners74.29%
Inst Owner Change5.06%
Ins Owners10.03%
Ins Owner Change-3.45%
Market Cap9.20B
Analysts68.89
Price Target108.43 (1.99%)
Short Float %2.94%
Short Ratio0.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.32%
Min EPS beat(2)-34.07%
Max EPS beat(2)-4.58%
EPS beat(4)0
Avg EPS beat(4)-60.23%
Min EPS beat(4)-192.46%
Max EPS beat(4)-4.58%
EPS beat(8)3
Avg EPS beat(8)-23.74%
EPS beat(12)4
Avg EPS beat(12)-23.95%
EPS beat(16)8
Avg EPS beat(16)-6.04%
Revenue beat(2)2
Avg Revenue beat(2)24.41%
Min Revenue beat(2)8.73%
Max Revenue beat(2)40.08%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)17.4%
EPS NQ rev (1m)418.27%
EPS NQ rev (3m)-55.36%
EPS NY rev (1m)142.68%
EPS NY rev (3m)58.44%
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)1.04%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 47.27
P/S 77.58
P/FCF N/A
P/OCF N/A
P/B 40.58
P/tB 40.68
EV/EBITDA N/A
EPS(TTM)-0.99
EYN/A
EPS(NY)2.25
Fwd EY2.12%
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.39
OCFYN/A
SpS1.37
BVpS2.62
TBVpS2.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.17%
ROE -72.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.49%
FCFM N/A
ROA(3y)-26.9%
ROA(5y)-28.47%
ROE(3y)-45.46%
ROE(5y)-41.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.23
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 100.83%
Cap/Sales 0.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.86
Quick Ratio 8.73
Altman-Z 17.25
F-Score2
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)19.84%
Cap/Depr(5y)14.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%114.77%
EPS Next Y123.49%
EPS Next 2Y74.39%
EPS Next 3Y58.05%
EPS Next 5Y57.72%
Revenue 1Y (TTM)N/A
Revenue growth 3Y1.86%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year994.08%
Revenue Next 2Y340.75%
Revenue Next 3Y203.91%
Revenue Next 5Y123.42%
EBIT growth 1Y-89.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year125.44%
EBIT Next 3Y118.37%
EBIT Next 5YN/A
FCF growth 1Y-137.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135%
OCF growth 3YN/A
OCF growth 5YN/A